{"id":"W4406104381","doi":"10.1038/s41591-024-03334-7","title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":96,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Center for Advancing Translational Sciences; Cancer Center, University of Colorado; University of California, San Francisco; Queen Mary University of London; Weill Cornell Medical College; Genentech; Centro de Investigación Biomédica en Red de Cáncer; Universidad de Navarra; Memorial Sloan-Kettering Cancer Center; University of Washington; Uppsala Universitet; Universiteit Gent; Johannes Gutenberg-Universität Mainz; University of Oklahoma Health Sciences Center; Universitair Ziekenhuis Gent; University of Southampton; Seagen; Akademiska Sjukhuset; Cedars-Sinai Medical Center; University of Oklahoma; Massachusetts General Hospital; National Cancer Institute; Gilead Sciences; Yale University; University Hospital Southampton NHS Foundation Trust; Deutsches Krebsforschungszentrum; Universitätsmedizin der Johannes Gutenberg-Universität Mainz; Yale Cancer Center","keywords":"Atezolizumab; Medicine; Immunogenicity; Tolerability; Immunotherapy; CD8; Oncology; Internal medicine; Immunology; Cancer; Immune system; Pembrolizumab; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008755115,0.0009768119,0.001359164,0.0003233952,0.0002371839,0.0006715395,0.0005308687,0.001170299,0.001841059],"category_scores_gemma":[0.0003899922,0.0003094607,0.0008787388,0.0002352336,0.000476991,0.0005414472,0.0002179173,0.001845616,0.0003400819],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005020196,"about_ca_system_score_gemma":0.0007216707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003809667,"about_ca_topic_score_gemma":0.0009415917,"domain_scores_codex":[0.9998012,0.00008568086,0.000007779402,0.00003864087,0.00002401026,0.00004273803],"domain_scores_gemma":[0.9997122,0.00006450699,0.00004927505,0.00003169885,0.0000220502,0.0001203316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6625535,0.06529105,0.003838965,0.001405517,0.001311257,0.0004193415,0.0002755303,0.004214009,0.07248298,0.0006553258,0.004355404,0.183197],"study_design_scores_gemma":[0.4776616,0.5046883,0.005562294,0.0000480392,0.0003036407,0.0003605855,0.00004160711,0.002226893,0.006553452,0.0002771479,0.002249423,0.00002713775],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953152,0.00191234,0.0003933123,0.00020018,0.00007812309,0.0007727515,0.0004360971,0.00005933964,0.0008328073],"genre_scores_gemma":[0.9921004,0.001806566,0.001031445,0.0004200839,0.0001041196,0.001280902,0.0009729415,0.00001887154,0.002264661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001841059,"threshold_uncertainty_score":0.006159008,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009365711283726631,"score_gpt":0.3398104727478319,"score_spread":0.3304447614641052,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}